Cargando…

Important Treatment Outcomes for Patients with Psoriatic Arthritis: A Multisite Qualitative Study

BACKGROUND: Psoriatic arthritis (PsA) is a variable and complex inflammatory condition. Symptoms can compromise physical function, reduce quality of life, and accrue significant health costs. Commonly used patient-reported outcomes largely reflect the professionals’ perspective, however it is not kn...

Descripción completa

Detalles Bibliográficos
Autores principales: Dures, Emma, Hewlett, Sarah, Lord, Jane, Bowen, Clive, McHugh, Neil, Tillett, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5534194/
https://www.ncbi.nlm.nih.gov/pubmed/28229377
http://dx.doi.org/10.1007/s40271-017-0221-4
_version_ 1783253735062896640
author Dures, Emma
Hewlett, Sarah
Lord, Jane
Bowen, Clive
McHugh, Neil
Tillett, William
author_facet Dures, Emma
Hewlett, Sarah
Lord, Jane
Bowen, Clive
McHugh, Neil
Tillett, William
author_sort Dures, Emma
collection PubMed
description BACKGROUND: Psoriatic arthritis (PsA) is a variable and complex inflammatory condition. Symptoms can compromise physical function, reduce quality of life, and accrue significant health costs. Commonly used patient-reported outcomes largely reflect the professionals’ perspective, however it is not known whether they capture what is important to patients. OBJECTIVE: The aim of our study was to identify treatment outcomes important to patients with PsA. METHODS: Eight focus groups that were audio recorded, transcribed, anonymised and analysed using inductive thematic analysis were conducted at five hospital sites. The full data set was analysed by the lead researcher, and subsets analysed by three team members (including patient partners). RESULTS: Overall, 41 patients sampled for a range of phenotypes and domains of disease activity participated in the study: 20 males; mean age 58 years (range 28–75, standard deviation [SD] 11.4); mean disease duration 9 years (range 0.5–39, SD 8.3); and mean Health Assessment Questionnaire score of 1 (range 0.0–2.5, SD 0.7). Over 60 outcomes were identified and grouped into four themes: (i) symptom alleviation (e.g. pain, fatigue, itchy skin, swelling, and reducing variability); (ii) reduction of disease impact (e.g. tiredness and pain, mobility and dexterity, deteriorating physical fitness, negative emotional responses, and strained relationships and social interactions); (iii) improved prognosis (e.g. slowing down disease progression, maintaining independence, and enhancing quality of life); and (iv) minimisation of treatment harm and burden (e.g. nausea, long-term effects, and administration and monitoring of treatments). CONCLUSIONS: Outcomes from treatments that are important to patients, which relate to impacts from PsA and its treatment that range beyond those outcomes commonly measured, were identified. These patient perspectives need to be considered when evaluating treatments.
format Online
Article
Text
id pubmed-5534194
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-55341942017-08-14 Important Treatment Outcomes for Patients with Psoriatic Arthritis: A Multisite Qualitative Study Dures, Emma Hewlett, Sarah Lord, Jane Bowen, Clive McHugh, Neil Tillett, William Patient Original Research Article BACKGROUND: Psoriatic arthritis (PsA) is a variable and complex inflammatory condition. Symptoms can compromise physical function, reduce quality of life, and accrue significant health costs. Commonly used patient-reported outcomes largely reflect the professionals’ perspective, however it is not known whether they capture what is important to patients. OBJECTIVE: The aim of our study was to identify treatment outcomes important to patients with PsA. METHODS: Eight focus groups that were audio recorded, transcribed, anonymised and analysed using inductive thematic analysis were conducted at five hospital sites. The full data set was analysed by the lead researcher, and subsets analysed by three team members (including patient partners). RESULTS: Overall, 41 patients sampled for a range of phenotypes and domains of disease activity participated in the study: 20 males; mean age 58 years (range 28–75, standard deviation [SD] 11.4); mean disease duration 9 years (range 0.5–39, SD 8.3); and mean Health Assessment Questionnaire score of 1 (range 0.0–2.5, SD 0.7). Over 60 outcomes were identified and grouped into four themes: (i) symptom alleviation (e.g. pain, fatigue, itchy skin, swelling, and reducing variability); (ii) reduction of disease impact (e.g. tiredness and pain, mobility and dexterity, deteriorating physical fitness, negative emotional responses, and strained relationships and social interactions); (iii) improved prognosis (e.g. slowing down disease progression, maintaining independence, and enhancing quality of life); and (iv) minimisation of treatment harm and burden (e.g. nausea, long-term effects, and administration and monitoring of treatments). CONCLUSIONS: Outcomes from treatments that are important to patients, which relate to impacts from PsA and its treatment that range beyond those outcomes commonly measured, were identified. These patient perspectives need to be considered when evaluating treatments. Springer International Publishing 2017-02-22 2017 /pmc/articles/PMC5534194/ /pubmed/28229377 http://dx.doi.org/10.1007/s40271-017-0221-4 Text en © The Author(s) 2017, corrected publication 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to Creative Commons license, and indicate if changes were made.
spellingShingle Original Research Article
Dures, Emma
Hewlett, Sarah
Lord, Jane
Bowen, Clive
McHugh, Neil
Tillett, William
Important Treatment Outcomes for Patients with Psoriatic Arthritis: A Multisite Qualitative Study
title Important Treatment Outcomes for Patients with Psoriatic Arthritis: A Multisite Qualitative Study
title_full Important Treatment Outcomes for Patients with Psoriatic Arthritis: A Multisite Qualitative Study
title_fullStr Important Treatment Outcomes for Patients with Psoriatic Arthritis: A Multisite Qualitative Study
title_full_unstemmed Important Treatment Outcomes for Patients with Psoriatic Arthritis: A Multisite Qualitative Study
title_short Important Treatment Outcomes for Patients with Psoriatic Arthritis: A Multisite Qualitative Study
title_sort important treatment outcomes for patients with psoriatic arthritis: a multisite qualitative study
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5534194/
https://www.ncbi.nlm.nih.gov/pubmed/28229377
http://dx.doi.org/10.1007/s40271-017-0221-4
work_keys_str_mv AT duresemma importanttreatmentoutcomesforpatientswithpsoriaticarthritisamultisitequalitativestudy
AT hewlettsarah importanttreatmentoutcomesforpatientswithpsoriaticarthritisamultisitequalitativestudy
AT lordjane importanttreatmentoutcomesforpatientswithpsoriaticarthritisamultisitequalitativestudy
AT bowenclive importanttreatmentoutcomesforpatientswithpsoriaticarthritisamultisitequalitativestudy
AT mchughneil importanttreatmentoutcomesforpatientswithpsoriaticarthritisamultisitequalitativestudy
AT importanttreatmentoutcomesforpatientswithpsoriaticarthritisamultisitequalitativestudy
AT tillettwilliam importanttreatmentoutcomesforpatientswithpsoriaticarthritisamultisitequalitativestudy